Research location
Tielt
Belgium
Advertisement
Research activity in Tielt
BelgiumCureCurrent currently publishes aggregate city-level research activity for this location: 21 trials and 21 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Tielt
21 linked trials · page 1 of 1The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical PracticeNCT02202837 · 2014-08-12 · 1 site observation
COMPLETED
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 DiabetesNCT01289990 · 2011-02-01 · 1 site observation
COMPLETED
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 DiabetesNCT01177813 · 2010-07-01 · 1 site observation
COMPLETED
Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 DiabetesNCT01006590 · 2009-10-01 · 1 site observation
COMPLETED
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD PatientsNCT00789854 · 2008-11-01 · 1 site observation
COMPLETED
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.NCT00681850 · 2008-03-01 · 1 site observation
COMPLETED
Quality of Life in Schizophrenic PatientsNCT00597168 · 2007-10-01 · 1 site observation
COMPLETED
A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical PracticeNCT00505388 · 2007-07-01 · 1 site observation
COMPLETED
Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary PreventionNCT00689377 · 2007-05-01 · 1 site observation
COMPLETED
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With SchizophreniaNCT00460512 · 2007-04-25 · 1 site observation
COMPLETED
Local Phase 4 Pan-European SMART StudyNCT00463866 · 2007-03-01 · 1 site observation
COMPLETED
TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in BelgiumNCT00886288 · 2006-09-01 · 1 site observation
COMPLETED
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant HypertensionNCT00389779 · 2006-09-01 · 1 site observation
COMPLETED
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive DisorderNCT00351910 · 2006-05-01 · 1 site observation
COMPLETED
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsNCT00286897 · 2006-02-01 · 1 site observation
COMPLETED
SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent AsthmaNCT00290264 · 2004-12-01 · 1 site observation
COMPLETED
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT00949910 · 2004-11-01 · 1 site observation
COMPLETED
Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate CancerNCT01081873 · 2004-06-01 · 1 site observation
COMPLETED
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's DiseaseNCT00058838 · 2003-04-01 · 1 site observation
COMPLETED
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/GlibenclamideNCT00279045 · 2000-01-03 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.